172 related articles for article (PubMed ID: 33097752)
1. Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches.
Güler R; Svedmark SF; Abouzayed A; Orlova A; Löfblom J
Sci Rep; 2020 Oct; 10(1):18148. PubMed ID: 33097752
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.
Fleetwood F; Klint S; Hanze M; Gunneriusson E; Frejd FY; Ståhl S; Löfblom J
Sci Rep; 2014 Dec; 4():7518. PubMed ID: 25515662
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.
Papo N; Silverman AP; Lahti JL; Cochran JR
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):14067-72. PubMed ID: 21825147
[TBL] [Abstract][Full Text] [Related]
5. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.
Grimm S; Salahshour S; Nygren PÅ
N Biotechnol; 2012 Jun; 29(5):534-42. PubMed ID: 22027369
[TBL] [Abstract][Full Text] [Related]
6. VEGFR2-Specific Ligands Based on Affibody Molecules Demonstrate Agonistic Effects when Tetrameric in the Soluble Form or Immobilized via Spider Silk.
Güler R; Thatikonda N; Ghani HA; Hedhammar M; Löfblom J
ACS Biomater Sci Eng; 2019 Dec; 5(12):6474-6484. PubMed ID: 33417800
[TBL] [Abstract][Full Text] [Related]
7. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast.
Traxlmayr MW; Faissner M; Stadlmayr G; Hasenhindl C; Antes B; Rüker F; Obinger C
Biochim Biophys Acta; 2012 Apr; 1824(4):542-9. PubMed ID: 22285845
[TBL] [Abstract][Full Text] [Related]
8. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
9. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
Getmanova EV; Chen Y; Bloom L; Gokemeijer J; Shamah S; Warikoo V; Wang J; Ling V; Sun L
Chem Biol; 2006 May; 13(5):549-56. PubMed ID: 16720276
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
11. A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity.
Lindberg H; Härd T; Löfblom J; Ståhl S
Biotechnol J; 2015 Sep; 10(11):1707-18. PubMed ID: 26184787
[TBL] [Abstract][Full Text] [Related]
12. Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69.
Persson J; Puuvuori E; Zhang B; Velikyan I; Åberg O; Müller M; Nygren PÅ; Ståhl S; Korsgren O; Eriksson O; Löfblom J
Sci Rep; 2021 Sep; 11(1):19151. PubMed ID: 34580321
[TBL] [Abstract][Full Text] [Related]
13. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
14. VEGFR2 Mimicking Peptide Inhibits the Proliferation of Human Umbilical Vein Endothelial Cells (Huvecs) by Blocking VEGF.
Ghasemali S; Barzegar A; Farajnia S; Rahmati M; Negahdari B; Etemadi A; Nazari A
Anticancer Agents Med Chem; 2023; 23(14):1678-1688. PubMed ID: 37194933
[TBL] [Abstract][Full Text] [Related]
15. Directed evolution of soluble single-chain human class II MHC molecules.
Esteban O; Zhao H
J Mol Biol; 2004 Jun; 340(1):81-95. PubMed ID: 15184024
[TBL] [Abstract][Full Text] [Related]
16. Autotransporter-Mediated Display of a Naïve Affibody Library on the Outer Membrane of Escherichia coli.
Andersson KG; Persson J; Ståhl S; Löfblom J
Biotechnol J; 2019 Apr; 14(4):e1800359. PubMed ID: 30179307
[TBL] [Abstract][Full Text] [Related]
17. Design of an optimized scaffold for affibody molecules.
Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
[TBL] [Abstract][Full Text] [Related]
18. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.
Lindborg M; Cortez E; Höidén-Guthenberg I; Gunneriusson E; von Hage E; Syud F; Morrison M; Abrahmsén L; Herne N; Pietras K; Frejd FY
J Mol Biol; 2011 Mar; 407(2):298-315. PubMed ID: 21277312
[TBL] [Abstract][Full Text] [Related]
19. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
20. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Mitran B; Güler R; Roche FP; Lindström E; Selvaraju RK; Fleetwood F; Rinne SS; Claesson-Welsh L; Tolmachev V; Ståhl S; Orlova A; Löfblom J
Theranostics; 2018; 8(16):4462-4476. PubMed ID: 30214632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
